Key facts
- It has raised $90.3M; the latest was Secondary Transaction - Private in Oct 2025.
- Notable investors include Qiming Venture Partners, Shanghai Highpower Industrial, HuaE Finance Management, Hunan Xiangjiang Xincheng Private Equity Fund Management, Ling Cheng Ventures — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Yuyao Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Yuyao Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Yuyao Biotechnology
Developer of new drugs designed for tumors, neurodegenerative diseases, autoimmune diseases and other diseases. The company offers small molecule drug discovery with artificial intelligence and the development of modern new drug technology, thereby treating major clinical unmet diseases.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2020
- Employees
- 50
- Website
- yuyaobiotech.com/
- Ownership
- Privately Held (backing)
Yuyao Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Yuyao Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Yuyao Biotechnology in its N-PORT filings yet. We sweep new filings monthly.